COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
Provided By GlobeNewswire
Last update: Nov 12, 2024
Continued execution on merger integration with Ceapro Inc. and advancements across business
Company ended the quarter with US$20.0 million in cash
Read more at globenewswire.com
